Aoquan Bio (奥全生物)

Shanghai Aoquan Biomedical Technology Co., Ltd. (Aoquan Bio) is an international biopharmaceutical company founded in 2019, dedicated to the R&D and industrialization of high-end improved formulations for unmet clinical needs. The company focuses on targeted drug improvements in pediatrics, vascular diseases, and antiviral fields, developing new dosage forms, new indications, and new dosing regimens approved by both the US FDA and China NMPA. Its R&D center is based in Pudong, Shanghai, with a US subsidiary Auson Pharmaceuticals Inc. in New Jersey handling product commercialization in North America.